Overview

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Status:
Terminated

Trial end date:
2019-04-08

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and effectiveness of this combination.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Celgene Corporation

Treatments:

BB 1101
Busulfan
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Enoxaparin
Gemcitabine
Lenalidomide
Melphalan
Pyridoxal
Pyridoxine
Rituximab
Thalidomide
Vitamin B 6
Vorinostat